Screener
Vaxcyte, Inc. PCVX CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued expenses | (15,571) | (4,393) |
| Net cash used in operating activities | (280,625) | (166,274) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (2,107) | (5,424) |
| Purchases of manufacturing facility build-out and equipment construction-in-progress | (12,687) | (21,327) |
| Purchases of investments | (584,129) | (314,485) |
| Maturities of investments | 340,631 | 438,488 |
| Sales of investments | 24,882 | 26,065 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s capex?
- Vaxcyte, Inc. (PCVX) reported capex of $2.11M in Q1 2026.
- How has Vaxcyte, Inc.'s capex changed year-over-year?
- Vaxcyte, Inc.'s capex decreased by 61.2% year-over-year, from $5.42M to $2.11M.
- What is the long-term trend for Vaxcyte, Inc.'s capex?
- Over 3 years (2021 to 2025), Vaxcyte, Inc.'s capex has grown at a 27.9% compound annual growth rate (CAGR), from $6.56M to $13.71M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Vaxcyte, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude